Investors are infatuated lately with preclinical biotech companies going public.
Six of these very young biotechs have managed successful initial public offerings this year, despite not yet securing regulators’ permission to start human clinical trials. By comparison, one preclinical biotech was able to go public last year.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
More opportunities for leveraged shorting down the line, eh Adam? As a lot, investors will lose money. see Feuerstein-Ratain rule. More Aeterna Zentaris companies here than future Amgens for sure.